Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DiaMedica Therapeutics Inc DMAC

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.


NDAQ:DMAC - Post by User

Bullboard Posts
Post by Sciencegeekon Nov 06, 2014 10:24pm
290 Views
Post# 23105040

The old shell game

The old shell gameLet's look at the facts. They have been running this clinical trial for quite some time so the fact that news is coming in the second week of November is no surprise to them. They are running a very simple clinical trial with few subjects so they have been getting news as it trickles in. They announced in October that they were going to finance at 25 cents with warrants at 32 cents and miraculously five days before the financing closes they receive news that the results are in and they have to cancel the planned financing and everyone goes hog wild thinking that they cancelled the financing because of some grand news that just appeared on their desk and put out a news release that night. I suspect that they probably had next to no response with their financing and went into panic mode and decided to put out the release and then take a second kick at the financing. I am not a basher and I do like the science of this company but I suspect the news will come out and we may see another rally but then as is the history of this company we will hear the crickets for another year until the pay checks don't clear and they have to go back for more financing. I'm happy for the people that bought this at 21 cents but I frankly don't see the excitement of a stock doubling to the levels it was at 3 weeks ago.
Bullboard Posts